Neurophet Names Josh Cohen Head of Americas to Drive North American Expansion
Neurophet has appointed Josh Cohen as Head of Americas Business, signaling a decisive push into the U.S., Canada, and South America. The move focuses on accelerating revenue, building distribution, and standing up customer success operations across the region.
Cohen brings more than a decade of commercialization experience in medical AI and imaging. His background includes senior roles at Philips, Cortechs.ai, Shared Imaging, and advisory and acting CCO work helping MRI AI companies launch and scale in the U.S. and abroad.
Why this hire matters
- Direct U.S. market play: Cohen will build the regional team, go-to-market engine, and customer success to support adoption.
- Competitive insight: He previously served as CCO at Cortechs.ai, a direct competitor in AI-driven brain imaging analysis.
- Distribution-first approach: Neurophet plans to establish partnerships across the Americas while tightening execution around sales operations.
Competitive context
Neurophet leads in Asia Pacific and is now turning that momentum toward the Americas. Cohen's track record-growing AI-based brain imaging products and expanding internationally-positions Neurophet to compete head-to-head with established players in the region.
His experience at Cortechs.ai gives Neurophet practical insight into buyer priorities, adoption barriers, and the commercial levers that matter most for imaging AI.
Executive perspectives
Josh Cohen, Head of Americas Business at Neurophet, said, "I am delighted to be part of Neurophet, a company with global competitiveness in the field of imaging analysis related to Alzheimer's disease treatment prescriptions and look forward to accelerating product sales by strengthening our entry into the North American market."
Jake Junkil Been, Co-CEO of Neurophet, added, "With Josh Cohen joining us, the pivotal leader behind the rapid growth of our key competitor Cortechs.ai, Neurophet is well-positioned to accelerate product deployment throughout the North American market. Looking ahead, we aim to expand our product offerings with a strong focus on major healthcare institutions across the United States."
What to watch from Neurophet in the Americas
- Regional build-out: Hiring across sales, clinical applications, and customer success to support hospital deployments.
- Partnerships: Distributor agreements and strategic collaborations to widen access across U.S., Canada, and South America.
- Commercial traction: Early reference sites, validated outcomes, and enterprise agreements with major healthcare systems.
Neurophet product portfolio
- Neurophet AQUA: Brain MRI analysis software.
- Neurophet SCALE PET: PET image quantitative analysis.
- Neurophet tES/TMS LAB: Treatment planning for electric and magnetic brain stimulation.
- Neurophet AQUA AD: Software for Alzheimer's disease treatment prescription and monitoring, including efficacy and side effects tracking.
- Neurophet AQUA MS: Image analysis software for multiple sclerosis.
Strategic takeaway for executives
This is a classic "experienced operator meets new market" bet. Expect Neurophet to prioritize large health systems, proof-driven sales motions, and scalable service models-critical for imaging AI where workflow fit and post-sale support make or break adoption.
Given Neurophet's focus on Alzheimer's-related imaging analysis, pay attention to clinical validation, integration with hospital IT, and alignment with care pathways. For context on Alzheimer's disease prevalence and care needs, see the U.S. National Institute on Aging overview of Alzheimer's disease.
Your membership also unlocks:
